Home >> News >> Business >> Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022

Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022

Product Summary

The study is given to the analysis of the latest growth trends and prospects for the  Irritable Bowel Syndrome With Diarrhea Drugs market.

The section ” Irritable Bowel Syndrome With Diarrhea Drugs Market” includes an examination of the situation in major sections of the  Irritable Bowel Syndrome With Diarrhea Drugs market. The markets in European Union countries are examined in more detail, giving a timeline of financial results reported by major 3PL providers in 2017.

Browse full report: https://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market

Market Insight:

IBS affects between 10% to 20% individuals in the developed countries. Since the underlying cause of IBD remains unknown, the treatment market for the same is observed to be unvisited and is characterized by very few indicated drugs. By far, alosetron has been the only drug approved for IBS-D treatment. With the approval for eluxadoline (Viberzi) and rifaximin (Xifaxan), new avenues in the IBS-D treatment market have opened, giving hopes to the patients.

Both Viberzi and Xifaxan are determined to be safe, Viberzi may receive controlled substance label due to risk of potential abuse. Viberzi and other IBS-D drugs act on opioid receptors, thus it is a mu receptor antagonist and kappa receptor antagonist. On the other hand, Xifaxan is viewed as a curative regimen, since it acts by altering the bacterial flora in the guts.
Xifaxan has been reportedly prescribed off label for treating IBS-D. Its formal sanction will thus support the growth in demand for the drug in the forecast period. Xifaxan is prescribed for a 14 day, thrice a day dosage; with a further additional 1 week dosage if the need arises. However, its long term role in efficiently containing IBS-D is still questioned. Viberzi, on the other hand, easily fits the profile of everyday medication for chronic disease treatment, similar to diabetes and CVD treatments. Further safety and effective assessments on these drugs are lined up, which will clear the market status of the two drugs.

The market for Viberzi is expected to cross USD 6 Mn mark by 2022, whereas Xifaxan market is expected to progress at a CAGR of moderate 4.46% during 2016-2022. IBS-D affects over 15 million Americans, with no single drugs having a clear domination in the market. Loperamide, angidepressants, alosetron, bile acid binders and similar such drugs were the standard treatments in the past. Medical professionals have largely relied on trial and error approach for treating IBS-D patients.

Global IBS-D Drugs Market Analysis, by Drugs
4.1 Preface
4.2 Eluxadoline
4.3 Alosetron
4.4 Rifaximin
4.5 Loperamide
4.6 Diphenoxylate + Atropine
4.7 Dicyclomine and Hyoscyamine
4.8 Pipeline Drug Analysis: Ibodutant
4.9 Pipeline Drug Analysis: Ramosetron

Chapter 5 Global IBS-D Drugs Market Analysis, By Prescription Type
5.1 Prescribed and OTC Drugs
5.2 Prescribed Branded and Prescribed Generic Drugs

Chapter 6 Global IBS-D Drugs Market Analysis, By Geography
6.1 Preface
6.2 North America
6.2.1 United States
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.4.3 Rest of Asia Pacific
6.5 Rest of the World (RoW)

Chapter 7 Company Profiles
7.1 Astellas Pharmaceuticals
7.1.1 Overview
7.1.2 Astellas Pharmaceuticals Product Portfolio
7.1.3 SCOT Analysis
7.2 Actavis
7.2.1 Overview
7.2.2 Actavis product portfolio
7.2.3 Strategic Moves
7.2.4 SCOT Analysis
7.3 Pfizer
7.3.1 Overview
7.3.2 Pfizer Product Portfolio
7.3.3 SCOT Analysis
7.4 GlaxoSmithKline
7.4.1 Overview
7.4.2 GlaxoSmithKline Product Portfolio
7.4.3 SCOT Analysis
7.5 Salix Pharmaceuticals Ltd
7.5.1 Overview
7.5.2 Salix Pharmaceuticals Product Portfolio
7.5.3 SCOT Analysis
7.6 AstraZenenca
7.6.1 Overview
7.6.2 Astrazeneca Product Portfolio
7.6.3 SCOT Analysis

“ Irritable Bowel Syndrome With Diarrhea Drugs Market” is a new report by us that explains how companies’ acquisition expenditures, media spend, business strategies, marketing and sales strategies and practices, and business plan are set to change in 2017-2018. This paper gives you access to the category-level spending forecasts, business challenges, budgets, supplier selection criteria, the current size of the marketing and promotion budgets and investment opportunities for senior-level officials. The report also identifies the expected growth of buyers and suppliers, capital expenditure, staff hiring, M and A, and e-procurement. This report not only gives access to the views and strategies of business decision makers and rivals but also examines their actions circling business priorities. The report also provides access to information categorized by company type and sizes, region,

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from Our Research’s elite panel of leading global senior level executives from enterprises such as such as medical devices, mining, packaging, power, oil, and gas, food and beverage, airports and pharmaceutical. The report covers key topics such as appropriation behaviors and strategies, the current size of the marketing and advertising budgets. Besides the report also recognizes the threats and possibilities, economic outlook trends, media channel spending outlooks, M and A expectations, marketing agency selection models, media budgets, business challenges and confidence among senior-level executives across various industries. Most secondary research papers are based on general industry drivers and do not understand the industry officials’ attitude and changing behaviors, creating a gap in showing the business opportunity of the industry. In an effort to bridge this gap, Our Research created this primary-research based report by selecting the opinions of various stakeholders in the value-chain of the industry

This report offers:

  • Analysis of several products, and regions that would provide the clear understanding of the ongoing and future trends in the global Irritable Bowel Syndrome With Diarrhea Drugs market
  • Assessment of market dynamics such as drivers, restraints, and opportunities prevalent in the market
  • Quantitative assessment of the current market size and future estimations for the period from 2016 to 2026, along with CAGRs for the period from 2018 to 2026
  • Company profiles that will highlight key information about the imperative players operating in the global Irritable Bowel Syndrome With Diarrhea Drugs devices market

Here you can get an updated sample on this report: https://www.credenceresearch.com/sample-request/57736

About us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in the Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

Contact Us:

Credence Research Inc.

105 N 1st ST #429


CA 95103

United States




Leave a Reply

Your email address will not be published. Required fields are marked *